Acute myeloid leukemia (AML) is an uncommon but potentially catastrophic diagnosis with
historically high mortality rates. The standard of care treatment remained unchanged for …

The first edition of the European LeukemiaNet (ELN) recommendations for diagnosis and
management of acute myeloid leukemia (AML) in adults, published in 2010, has found …

Acquired mutations are pervasive across normal tissues. However, understanding of the
processes that drive transformation of certain clones to cancer is limited. Here we study this …

There is a growing body of evidence that therapy-related myeloid neoplasms (t-MNs) with
driver gene mutations arise in the background of clonal hematopoiesis (CH) under the …

Therapy-related myeloid neoplasms (t-MN) arise as a late effect of chemotherapy and/or
radiation administered for a primary condition, typically a malignant disease, solid organ …

Therapy-related acute myeloid leukemia (t-AML), defined as AML arising from prior
cytotoxic, radiation, or immunosuppressive therapy for an unrelated disease, accounts for …

PURPOSE To develop recommendations for systemic therapy for well-differentiated grade 1
(G1) to grade 3 (G3) metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs) …

Therapy-related myeloid neoplasms (t-MNs) include diseases onsetting in patients treated
with chemo-and/or radiotherapy for a primary cancer, or an autoimmune disorder. Genomic …

Secondary acute myeloid leukemia (sAML) poorly responds to conventional treatments and
allogeneic stem cell transplantation (HSCT). We evaluated toxicity and efficacy of CPX-351 …

Studies of therapy-related AML (t-AML) are usually performed in selected cohorts and
reliable incidence rates are lacking. In this study, we characterized, defined the incidence …